Announced
Completed
Financials
Sources
Tags
United States
Acquisition
software development
Software
Completed
Friendly
Domestic
medical software
Single Bidder
Private Equity
Private
Venture Capital
Synopsis
A consortium of investors, including Biovision Ventures, MedTex Ventures, IAG Capital, Bold Brain Ventures, and BlueStone Venture Partners, led a $27m Series B round in Elucid, a company developing a novel, non-invasive medical software. "Elucid is committed to providing physicians the most rigorously validated diagnostic platform to fight cardiovascular disease. Every patient is different and needs to be treated specific to his or her individual disease. We are so proud of the remarkable work our team has accomplished and this Series B allows us to expand our commercial reach. We warmly welcome our new investors and are grateful to our existing investors for their continued support in achieving our mission," Blake Richards, Elucid Chief Executive Officer.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.